- Which of the following is the most appropriate advice regarding her medication?
Answer: Continue sulfasalazine and add folic acid supplementation.
When managing inflammatory bowel disease during pregnancy, you must balance maternal disease control with fetal safety. Active IBD poses greater risks to both mother and fetus than most maintenance medications, making continued treatment crucial.
Sulfasalazine is considered safe during pregnancy and is classified as FDA Pregnancy Category B. The drug has been used extensively in pregnant women with IBD and rheumatoid arthritis without increased teratogenic risk. However, sulfasalazine does have one important mechanism of action that requires attention: it inhibits folate absorption and metabolism. Since adequate folate is essential for preventing neural tube defects, especially during the first trimester, folic acid supplementation (typically 5mg daily) should be added when continuing sulfasalazine during pregnancy.
Option A is incorrect because reducing the dose risks losing disease control without providing additional safety benefits. Option B is dangerous because discontinuing effective maintenance therapy significantly increases the risk of disease flare, which poses substantial risks including preterm labor, low birth weight, and maternal complications. Option C represents unnecessary switching since sulfasalazine is already safe in pregnancy, and topical mesalamine may be less effective for maintaining systemic disease control.
Remember for USMLE Step 3: IBD management during pregnancy prioritizes maintaining remission over medication concerns. Most IBD maintenance medications (sulfasalazine, mesalamine, certain immunosuppressants) are safer than active disease. Always consider adding folic acid when sulfasalazine is used in pregnancy due to folate interference.
- Which of the following is the most appropriate next step in her management?
Answer: Add infliximab therapy.
This patient has active Crohn disease despite being on an optimized dose of azathioprine (as evidenced by therapeutic 6-TGN levels). This represents a failure of immunomodulator monotherapy. The next step is to escalate therapy by adding a biologic agent, such as the anti-TNF agent infliximab. Increasing azathioprine is incorrect as levels are already therapeutic. Switching to another immunomodulator like methotrexate is less effective than escalating to a biologic. Budesonide is used for short-term induction of remission but does not address the need for a change in long-term maintenance strategy.
- Which of the following is the most appropriate long-term medical therapy for this condition?
Answer: Initiation of an anti-TNF biologic agent like infliximab.
Complex perianal fistulas are a serious complication of Crohn disease and require aggressive medical management to promote healing and prevent complications. Anti-TNF agents (e.g., infliximab, adalimumab) are the cornerstone of therapy for fistulizing Crohn disease and have been shown to induce and maintain fistula closure. Antibiotics can be used as an adjunct or for associated abscesses but are not effective as long-term monotherapy for fistula healing. Surgical fistulotomy carries a high risk of incontinence with a high (transsphincteric) fistula. Budesonide has minimal systemic effect and is not effective for fistulizing disease.
- Which of the following screening tests is most critical to perform before administering the first dose of adalimumab?
Answer: Interferon-gamma release assay.
Anti-TNF agents like adalimumab can cause reactivation of latent tuberculosis (TB). Therefore, all patients must be screened for latent TB infection before initiating therapy. An interferon-gamma release assay (IGRA) or a tuberculin skin test are the standard screening methods. TPMT testing is done before starting thiopurines (azathioprine, 6-mercaptopurine). Hepatitis B screening is also important before starting anti-TNF therapy, but latent TB is a major contraindication and requires treatment before starting the biologic. A colonoscopy has likely already been done to make the diagnosis of Crohn's.
- Which of the following is the most appropriate next step in management?
Answer: Escalate therapy for her Crohn disease.
When you encounter iron deficiency anemia in inflammatory bowel disease patients, you need to distinguish between simple iron deficiency and iron deficiency secondary to active inflammation. The key is recognizing that untreated inflammation prevents effective iron absorption and utilization, making iron supplementation futile until the underlying disease is controlled.
This patient has classic iron deficiency anemia (low hemoglobin, low MCV, low ferritin, low transferrin saturation) but the critical clue is her markedly elevated fecal calprotectin of 650 mcg/g. Calprotectin is a biomarker of intestinal inflammation - normal levels are under 50 mcg/g, and her level indicates severely active Crohn disease. The failure to respond to 3 months of oral iron therapy despite appropriate supplementation confirms that active inflammation is blocking iron absorption and utilization through hepcidin-mediated mechanisms.
Option D is correct because controlling the underlying Crohn disease inflammation is essential before iron therapy can be effective. Without treating the active disease, any form of iron supplementation will likely fail.
Option A (IV iron) might seem logical since oral iron failed, but IV iron won't work effectively while severe inflammation persists. Option B (transfusion) isn't indicated - her hemoglobin of 9.8 g/dL, while low, doesn't meet transfusion thresholds in a stable patient. Option C (higher oral iron dose) ignores that absorption is impaired due to inflammation, not inadequate dosing.
Remember: In IBD patients with refractory iron deficiency anemia, always check inflammatory markers. Treat the inflammation first, then reassess iron status.
- Which of the following medications would be the most appropriate next choice for this patient?
Answer: Ustekinumab.
This patient has demonstrated a primary non-response to an anti-TNF agent with adequate drug levels, suggesting that the TNF pathway is not the optimal therapeutic target for his disease. In this situation, switching to a biologic with a different mechanism of action is recommended. Ustekinumab, which targets interleukins 12 and 23, is an effective and appropriate choice. Switching to another anti-TNF agent (infliximab, certolizumab) is less likely to be effective in a primary non-responder. Methotrexate is an immunomodulator and would not be potent enough for this patient who has already failed a first-line biologic.
- Which of the following is the most appropriate next step in the management of her skin condition?
Answer: Initiate systemic corticosteroid therapy.
The patient's skin lesions are characteristic of erythema nodosum, an extraintestinal manifestation of IBD. The activity of erythema nodosum typically parallels the activity of the underlying bowel disease. Her worsening gastrointestinal symptoms suggest a flare of her Crohn disease. The primary treatment for erythema nodosum in this context is to treat the underlying IBD flare, which typically involves initiating systemic corticosteroids. NSAIDs can exacerbate IBD and should be avoided. A skin biopsy is not usually necessary for classic lesions. Topical steroids are ineffective.
- Which of the following is the most likely diagnosis?
Answer: Drug-induced lupus erythematosus.
The clinical presentation of arthritis, malar rash, and new-onset positive ANA and anti-dsDNA antibodies in a patient treated with an anti-TNF agent like infliximab is characteristic of drug-induced lupus erythematosus. While serum sickness-like reactions can occur, they are less likely to be associated with the specific seroconversion to anti-dsDNA. Crohn's-associated arthritis is typically seronegative. New-onset rheumatoid arthritis is less likely given the temporal relationship to the drug and the specific autoantibody profile.
- What is the most appropriate recommendation for de-escalating his therapy?
Answer: Discontinue azathioprine and continue infliximab monotherapy.
In patients with IBD on combination therapy with a biologic and an immunomodulator who are in deep, sustained remission, de-escalation can be considered. Evidence suggests that discontinuing the immunomodulator (azathioprine) while continuing the biologic (infliximab) maintains remission rates better than the reverse and reduces the risk of infections and non-melanoma skin cancer associated with long-term thiopurine use. Discontinuing the biologic carries a high risk of relapse. Stopping both medications would likely lead to a flare.
- In addition to administering age-appropriate inactivated vaccines, which of the following is the most important recommendation regarding her vaccination status before starting therapy?
Answer: Administer the live attenuated varicella vaccine series.
Patients who are candidates for immunosuppressive biologic therapy should have their vaccination status updated prior to initiation. This is particularly critical for live vaccines, such as the varicella vaccine, which are contraindicated once immunosuppressive therapy has started. The vaccine series should be completed at least 4 weeks before the first dose of the biologic. VZIG is used for post-exposure prophylaxis, not for primary immunization.
- Which of the following is the most appropriate screening for this patient at this time?
Answer: Dual-energy X-ray absorptiometry (DEXA) scan.
This patient has multiple risk factors for osteoporosis, including inflammatory bowel disease itself (a risk factor for malabsorption and chronic inflammation), postmenopausal status, and a history of significant corticosteroid use (≥3 months cumulative in the past). Therefore, she meets the criteria for osteoporosis screening with a DEXA scan. While monitoring vitamin D and calcium is important, it is not a screening test for bone mineral density. The risk from steroids is cumulative. Plain radiographs are insensitive for detecting early bone loss.
- In addition to his routine IBD care, which of the following surveillance strategies is now indicated?
Answer: Annual colonoscopy with random biopsies.
When you encounter a patient with both inflammatory bowel disease (IBD) and primary sclerosing cholangitis (PSC), you need to understand that this combination dramatically increases colorectal cancer risk. PSC occurs in about 5% of ulcerative colitis patients, but when present, it creates a synergistic effect that accelerates malignant transformation in the colon.
The correct answer is D because patients with UC and concurrent PSC require annual colonoscopy with random biopsies throughout the colon, even when asymptomatic. The random biopsies are crucial because dysplasia in PSC patients can be flat and invisible to standard endoscopy. This intensive surveillance should begin immediately upon PSC diagnosis, regardless of UC duration or current disease activity.
Option A is dangerous because quiescent colitis doesn't eliminate cancer risk - in fact, PSC patients can develop colorectal cancer even with inactive IBD. Option B reflects outdated practice; ERCP with brushings was once used for cholangiocarcinoma surveillance but has been largely abandoned due to poor sensitivity and procedure-related risks. Option C addresses the wrong organ system - while PSC patients do have increased hepatobiliary malignancy risk, gallbladder polyp surveillance isn't the established standard.
Remember this key association: IBD + PSC = immediate upgrade to annual colonoscopy with random biopsies. This is one of the highest-risk scenarios for colorectal cancer in gastroenterology, requiring the most aggressive surveillance protocol regardless of symptom status or previous normal examinations.
- According to current guidelines, what is the most appropriate recommendation for this patient's next colorectal cancer surveillance?
Answer: Repeat colonoscopy in 1 to 2 years.
Patients with long-standing (≥8 years) extensive ulcerative colitis are at high risk for colorectal cancer. Surveillance colonoscopy is recommended every 1 to 2 years for patients with pancolitis. The risk is determined by the duration and extent of disease, not solely by current inflammatory activity. Fecal immunochemical testing is not an adequate surveillance method for IBD-associated cancer risk. A 5-year interval is too long for a high-risk patient with pancolitis.
- Which of the following is the most appropriate initial response?
Answer: Acknowledge their concerns and discuss the risks of untreated moderate-to-severe Crohn disease, such as strictures and surgery.
The best approach involves shared decision-making. This begins with validating the patient's concerns, which are based on real, though often small, risks. The next crucial step is to provide balanced information, contrasting the risks of the medication with the significant risks of inadequately treated Crohn disease, including bowel damage, malnutrition, fistulas, abscesses, and the need for surgery. Dismissing their concerns (B) is counterproductive. Prescribing an ineffective therapy like a 5-ASA for moderate disease (C) is inappropriate. Surgical referral (D) is premature before medical options are fully explored and discussed.
- Which of the following is the most likely diagnosis?
Answer: Pouchitis.
Pouchitis, or inflammation of the ileal pouch, is the most common long-term complication after IPAA for ulcerative colitis. The symptoms of increased stool frequency, cramping, and urgency are classic for this condition. While Crohn disease of the pouch can occur, it is less common, especially if the original diagnosis was definitive UC. Irritable pouch syndrome is a diagnosis of exclusion. Small intestinal bacterial overgrowth typically presents with more bloating and flatulence. Given the inflammatory nature of the symptoms, pouchitis is the most probable diagnosis and is typically treated with antibiotics like ciprofloxacin or metronidazole.
- Which of the following is the most appropriate next step to guide further management?
Answer: Perform a flexible sigmoidoscopy to assess for mucosal healing.
This patient has had a partial clinical response to ustekinumab. The next step is to objectively assess for endoscopic improvement (mucosal healing), which is a key therapeutic goal in IBD and a better predictor of long-term outcomes than symptoms alone. A flexible sigmoidoscopy is the best way to evaluate this. If there is ongoing inflammation, management changes (e.g., dose optimization) may be considered. Checking drug levels can be useful, but objective assessment of inflammation is paramount. Switching therapy is premature without endoscopic assessment. Adding mesalamine is unlikely to provide significant benefit in a patient with moderate-to-severe disease already on a potent biologic.
- This patient's underlying inflammatory bowel disease is most likely which of the following?
Answer: Crohn disease.
The presence of a phlegmon, transmural inflammation, stricturing disease, and small bowel involvement (terminal ileum) are all characteristic features of Crohn disease. Ulcerative colitis is a mucosal disease limited to the colon and does not typically cause phlegmons or small bowel obstruction. Microscopic colitis causes watery diarrhea and has normal endoscopic findings. Indeterminate colitis is used when features overlap, but this presentation is strongly suggestive of Crohn disease.
- Which of the following is the most appropriate next step in her outpatient management?
Answer: Add a 4-week course of oral prednisone.
When you encounter a patient with known ulcerative colitis presenting with worsening symptoms, you need to assess disease severity and choose appropriate step-up therapy. This patient shows clear signs of a mild-to-moderate flare: increased stool frequency, urgency, bloody stools, and elevated inflammatory markers, but remains hemodynamically stable.
The correct approach is adding oral prednisone (D). Since her current mesalamine therapy isn't controlling the flare, you need to escalate to corticosteroids. Oral prednisone is appropriate for mild-to-moderate flares in hemodynamically stable outpatients. A 4-week course allows sufficient time for induction of remission while minimizing long-term steroid exposure.
Option A is incorrect because broad-spectrum antibiotics aren't indicated for UC flares unless there's clear evidence of superimposed infection, which isn't suggested here. Option B simply increasing mesalamine dose is insufficient since she's already on high-dose therapy and experiencing breakthrough symptoms - this represents treatment failure requiring escalation. Option C recommends inpatient IV corticosteroids, but this patient doesn't meet criteria for severe colitis (she's hemodynamically stable with moderate symptoms), making outpatient oral therapy appropriate.
The key distinction is recognizing mild-moderate versus severe UC flares. Severe flares require hospitalization and IV steroids, while mild-moderate flares can be managed outpatient with oral corticosteroids. Watch for hemodynamic stability, frequency of bloody stools, and overall clinical picture to guide this decision. Remember the step-wise approach: mesalamine → oral steroids → IV steroids/immunosuppressants.
